Balancing Treatment Benefits of Androgen-Receptor Signal Inhibitors and Quality of Life in Patients With Prostate Cancer
A partir d'une revue systématique de la littérature (12 études incluant un total de 13 524 patients), cette méta-analyse évalue l'effet, sur les fonctions cognitives et le risque de chute ou d'asthénie, des anti-androgènes de seconde génération (abiratérone, apalutamide, darolutamide ou enzalutamide) chez des patients atteints d'un cancer de la prostate
Prostate cancer is a serious health concern that affects millions of men worldwide. Treatment options for this disease include surgery, radiation therapy, and hormone therapy, among others. In recent years, androgen-receptor signal inhibitors (ARSIs) have gained popularity as a treatment option for prostate cancer. Abiraterone, which was first approved for men with metastatic castration-resistant prostate cancer (mCRPC) in 2011, was followed by enzalutamide’s approval for mCRPC in 2012. In 2018, abiraterone demonstrated an overall survival benefit of 18.2 months in men with metastatic hormone-sensitive prostate cancer and was approved by the US Food and Drug Administration for use in this setting.
JAMA Oncology , commentaire, 2022